Failure medications used after initial therapy
| Failure medication* . | Total (N = 358) . | Nonprednisone (N = 59) . | Prednisone only (N = 209) . | Prednisone + other agent(s) (N = 90) . |
|---|---|---|---|---|
| Sirolimus | 79 (19%) | 8 (14%) | 47 (22%) | 24 (27%) |
| Prednisone | 74 (18%) | 30 (51%) | 28 (13%) | 16 (18%) |
| MMF | 55 (13%) | 3 (5.1%) | 38 (18%) | 14 (16%) |
| ECP | 36 (8.6%) | 5 (8.5%) | 21 (10%) | 10 (11%) |
| Rituximab | 35 (8.4%) | 5 (8.5%) | 22 (11%) | 8 (8.9%) |
| Tacrolimus | 33 (7.9%) | 4 (6.8%) | 21 (10%) | 8 (8.9%) |
| Cyclosporine | 21 (5.0%) | 2 (3.4%) | 18 (8.6%) | 1 (1.1%) |
| MTX | 21 (5.0%) | 2 (3.4%) | 12 (5.7%) | 7 (7.8%) |
| Imatinib | 15 (3.6%) | 5 (8.5%) | 8 (3.8%) | 2 (2.2%) |
| Methylprednisolone | 9 (2.2%) | 1 (1.7%) | 4 (1.9%) | 4 (4.4%) |
| Interleukin-2 | 7 (1.7%) | 4 (1.9%) | 3 (3.3%) | |
| Hydroxychloroquine | 4 (1.0%) | 1 (1.7%) | 1 (0.5%) | 2 (2.2%) |
| Jakafi | 4 (1.0%) | 2 (3.4%) | 2 (1.0%) | |
| Ibrutinib | 3 (0.7%) | 1 (1.7%) | 1 (0.5%) | 1 (1.1%) |
| Nilotinib | 3 (0.7%) | 3 (1.4%) | ||
| Velcade | 3 (0.7%) | 2 (1.0%) | 1 (1.1%) | |
| Alemtuzumab | 2 (0.5%) | 2 (1.0%) | ||
| Infliximab | 2 (0.5%) | 2 (2.2%) | ||
| KD025 | 2 (0.5%) | 2 (1.0%) | ||
| Lenalidomide | 2 (0.5%) | 1 (0.5%) | 1 (1.1%) | |
| Tocilizumab | 2 (0.5%) | 2 (2.2%) | ||
| Other IST | 1 (0.2%) | 1 (0.5%) | ||
| ATG | 1 (0.2%) | 1 (0.5%) | ||
| Azathioprine | 1 (0.2%) | 1 (1.1%) | ||
| Dasatinib | 1 (0.2%) | 1 (0.5%) | ||
| Ofatumumab | 1 (0.2%) | 1 (1.1%) | ||
| Pentostatin | 1 (0.2%) | 1 (1.1%) |
| Failure medication* . | Total (N = 358) . | Nonprednisone (N = 59) . | Prednisone only (N = 209) . | Prednisone + other agent(s) (N = 90) . |
|---|---|---|---|---|
| Sirolimus | 79 (19%) | 8 (14%) | 47 (22%) | 24 (27%) |
| Prednisone | 74 (18%) | 30 (51%) | 28 (13%) | 16 (18%) |
| MMF | 55 (13%) | 3 (5.1%) | 38 (18%) | 14 (16%) |
| ECP | 36 (8.6%) | 5 (8.5%) | 21 (10%) | 10 (11%) |
| Rituximab | 35 (8.4%) | 5 (8.5%) | 22 (11%) | 8 (8.9%) |
| Tacrolimus | 33 (7.9%) | 4 (6.8%) | 21 (10%) | 8 (8.9%) |
| Cyclosporine | 21 (5.0%) | 2 (3.4%) | 18 (8.6%) | 1 (1.1%) |
| MTX | 21 (5.0%) | 2 (3.4%) | 12 (5.7%) | 7 (7.8%) |
| Imatinib | 15 (3.6%) | 5 (8.5%) | 8 (3.8%) | 2 (2.2%) |
| Methylprednisolone | 9 (2.2%) | 1 (1.7%) | 4 (1.9%) | 4 (4.4%) |
| Interleukin-2 | 7 (1.7%) | 4 (1.9%) | 3 (3.3%) | |
| Hydroxychloroquine | 4 (1.0%) | 1 (1.7%) | 1 (0.5%) | 2 (2.2%) |
| Jakafi | 4 (1.0%) | 2 (3.4%) | 2 (1.0%) | |
| Ibrutinib | 3 (0.7%) | 1 (1.7%) | 1 (0.5%) | 1 (1.1%) |
| Nilotinib | 3 (0.7%) | 3 (1.4%) | ||
| Velcade | 3 (0.7%) | 2 (1.0%) | 1 (1.1%) | |
| Alemtuzumab | 2 (0.5%) | 2 (1.0%) | ||
| Infliximab | 2 (0.5%) | 2 (2.2%) | ||
| KD025 | 2 (0.5%) | 2 (1.0%) | ||
| Lenalidomide | 2 (0.5%) | 1 (0.5%) | 1 (1.1%) | |
| Tocilizumab | 2 (0.5%) | 2 (2.2%) | ||
| Other IST | 1 (0.2%) | 1 (0.5%) | ||
| ATG | 1 (0.2%) | 1 (0.5%) | ||
| Azathioprine | 1 (0.2%) | 1 (1.1%) | ||
| Dasatinib | 1 (0.2%) | 1 (0.5%) | ||
| Ofatumumab | 1 (0.2%) | 1 (1.1%) | ||
| Pentostatin | 1 (0.2%) | 1 (1.1%) |
Those with multiple medications as their failure therapy are included for each individual medication.